4th Quarter - Report

WALGREEN COMPANY for WALGREEN COMPANY

Period 4th Quarter 2022 Filed Jan 20, 2023 Signed by G. Joel Baise, Director, Government Relations

Official filing
Firm
WALGREEN COMPANY
Client
WALGREEN COMPANY
Income
—
Expenses
$420,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Issues related to pharmacy provider status. H.R. 7213 Equitable Community Access to Pharmacist Services Act; issues related to access to pharmacist services. H.R. 7845 NIH Clinical Trial Diversity Act of 2022; issues related to access to pharmacist services.

LobbyistCovered position, as disclosed
MADELINE KAY HODGE —
KATIE L SMITH New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 7213 (117th), H.R. 7845 (117th)

Consumer Issues/Safety/Products CSP

S. 936/H.R. 5502: INFORM Consumers Act; provisions related to online marketplace transparency. Issues related to organized retail crime.

LobbyistCovered position, as disclosed
MADELINE KAY HODGE —
KATIE L SMITH New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5502 (117th), S. 936 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.